Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as gemtuzumab, can block cancer growth in different ways. Some
block the ability of cancer cells to grow and spread. Others find cancer cells and help kill
them or carry cancer-killing substances to them. Giving clofarabine together with gemtuzumab
may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of clofarabine when
given together with gemtuzumab in treating patients with relapsed or refractory acute myeloid
leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
Genzyme, a Sanofi Company National Cancer Institute (NCI)